financetom
Business
financetom
/
Business
/
Applied Industrial's Fiscal Q3 Earnings, Revenue Rise; Revises Fiscal 2025 Earnings Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Applied Industrial's Fiscal Q3 Earnings, Revenue Rise; Revises Fiscal 2025 Earnings Outlook
May 25, 2025 11:19 PM

09:17 AM EDT, 05/01/2025 (MT Newswires) -- Applied Industrial Technologies ( AIT ) reported fiscal Q3 earnings Thursday of $2.57 per diluted share, up from $2.48 a year earlier.

Four analysts surveyed by FactSet expected $2.40.

Revenue for the quarter ended March 31 was $1.17 billion, up from $1.15 billion a year earlier.

Analysts surveyed by FactSet expected $1.17 billion.

For fiscal 2025, the company revised its earnings outlook to now be between $9.85 and $10 from its previous outlook of between $9.65 and $10.05.

Analysts polled by FactSet expect $9.93.

Shares of the company were down more than 2% in recent premarket activity Thursday.

Price: 236.75, Change: -6.53, Percent Change: -2.68

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Rhythm Pharmaceuticals Says EMA Committee Backs Expanded Authorization for Obesity Drug
Rhythm Pharmaceuticals Says EMA Committee Backs Expanded Authorization for Obesity Drug
Jun 28, 2024
10:35 AM EDT, 06/28/2024 (MT Newswires) -- Rhythm Pharmaceuticals ( RYTM ) said Friday it had received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, recommending an expanded marketing authorization for Imcivree to include children between 2 and 6 years old with neuroendocrine diseases. The company said it expects a decision from the...
Mirum Pharmaceuticals Submits New Drug Application for Cholesterol Metabolism Treatment
Mirum Pharmaceuticals Submits New Drug Application for Cholesterol Metabolism Treatment
Jun 28, 2024
10:34 AM EDT, 06/28/2024 (MT Newswires) -- Mirum Pharmaceuticals ( MIRM ) said Friday that it has submitted a new drug application for chenodiol for treating patients with cerebrotendinous xanthomatosis, or CTX, in the US. CTX is a rare progressive disorder of cholesterol metabolism that can affect the brain, spinal cord, tendons, eyes, and arteries, the company said. The submission...
What's Going On With Palantir Technologies Shares Today?
What's Going On With Palantir Technologies Shares Today?
Jun 28, 2024
Palantir Technologies Inc. ( PLTR ) shares are trading marginally higher on Friday. Peter Thiel, Chairman of Palantir Technologies ( PLTR ), shared his outlook on the future in an NBC News interview. He focused on AI, digital currencies, and his views on America’s current state. In an interview with BNN Bloomberg, Dan Ives, an analyst at Wedbush Securities, dismissed the notion...
Kirby Insider Sold Shares Worth $360,930, According to a Recent SEC Filing
Kirby Insider Sold Shares Worth $360,930, According to a Recent SEC Filing
Jun 28, 2024
10:36 AM EDT, 06/28/2024 (MT Newswires) -- David W Grzebinski, Director, CEO, on June 26, 2024, sold 3,000 shares in Kirby (KEX) for $360,930. Following the Form 4 filing with the SEC, Grzebinski has control over a total of 63,399 shares of the company, with 63,399 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/56047/000095017024078824/xslF345X03/ownership.xml Price: 121.15, Change: +1.10, Percent Change: +0.92 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved